课题基金 / 基金详情

INGESTED INTERFERON ALPHA--BIOLOGIC /CLINICAL EFFECT IN RHEUMATOID ARTHRITIS

INGESTED INTERFERON ALPHA--BIOLOGIC /CLINICAL EFFECT IN RHEUMATOID ARTHRITIS
摄入干扰素α——对类风湿性关节炎的生物/临床作用
批准号：
6281677
负责人：
STALEY armstrong BROD
金额：
$1.36万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281677
关键词：
clinical research drug adverse effect drug screening /evaluation human subject human therapy evaluation immunopathology chemotherapy interferon alpha joint stiffness oral administration rheumatoid arthritis synovitis

项目摘要

项目成果

STALEY armstrong BROD的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this Phase I study is to determine whether ingested interferon-alpha (IFN-a) can decrease active synovitis, patient and physician global assessment of disease activity, and duration of morning stiffness in patients with rheumatoid arthritis, an autoimmune disease. Patients will receive 30,000 units of IFN-a on alternate days for two months. Every two weeks, assessment of symptoms will be performed by a rheumatologist. Tests for toxicity and immunological functions will be performed at each clinic visit. Four patients were enrolled in this study, which is now closed. Results have been submitted in manuscript form.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IFNA: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES MELLITUS
PREVENTION OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE VIA INGESTED IFN-ALPHA
PROTEIN BIOMARKERS OF IFN-ALPHA IN MS
INGESTED IFN-A: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES